Home › Triple-Negative Breast Cancer › North Carolina › Durham
Pag-aaral pangklinika para sa Triple-Negative Breast Cancer sa Durham, NC
Isang pag-aaral para sa Triple-Negative Breast Cancer ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Durham. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Nagre-recruitPhase 1/2
- Duke University, Durham
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Nagre-recruitPhase 2
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi ang layo
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Nagre-recruitPhase 3
- Duke Cancer Institute, Durham
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Nagre-recruitPhase 2
- Duke University, Durham
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Nagre-recruitPhase 2/3
- Duke Cancer Institute, Durham
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Nagre-recruitPhase 2
- Duke University Medical Center, Durham
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
Nagre-recruitPhase 1
- University of North Carolina, Chapel Hill · 10 mi ang layo
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Nagre-recruitPhase 1
- Duke Cancer Institute /ID# 276267, Durham
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Nagre-recruitPhase 2
- The University of North Carolina at Chapel Hill, Chapel Hill · 10 mi ang layo
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
Nagre-recruitPhase 2
- University of North Carolina, Chapel Hill · 10 mi ang layo
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
Nagre-recruitPhase 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo
A Study of NX-1607 in Adults With Advanced Malignancies
Nagre-recruitPhase 1
- University of North Carolina, Chapel Hill · 10 mi ang layo
Pag-aaral para sa Triple-Negative Breast Cancer sa ibang lungsod
- Houston, TX42 pag-aaral
- New York City, NY31 pag-aaral
- Nashville, TN28 pag-aaral
- Los Angeles, CA27 pag-aaral
- Boston, MA26 pag-aaral
- San Antonio, TX23 pag-aaral
- St. Louis, MO21 pag-aaral
- Arlington, VA20 pag-aaral
- Atlanta, GA20 pag-aaral
- Dallas, TX18 pag-aaral
- Chicago, IL16 pag-aaral
- Columbus, OH16 pag-aaral
Iba pang pag-aaral sa Durham
- Kanser sa Suso64 pag-aaral
- Kanser (lahat ng uri)58 pag-aaral
- Non-Small Cell Lung Cancer39 pag-aaral
- Multiple Myeloma37 pag-aaral
- Acute Myeloid Leukemia33 pag-aaral
- Metastatic Cancer33 pag-aaral
- Kanser sa Prostate32 pag-aaral
- Kanser sa Baga32 pag-aaral
- Colorectal Cancer28 pag-aaral
- Kanser sa Ovary27 pag-aaral
- Chronic Lymphocytic Leukemia27 pag-aaral
- Pagkabigo ng Puso26 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.